Brief: HLS Therapeutics Announces Q3 2024 Financial Results
07/11/2024 13:23
Nov 7 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES Q3 2024 FINANCIAL RESULTS
* HLS THERAPEUTICS: NAMED JOHN HANNA PERMANENT CFO AND
PROMOTED
BRIAN WALSH TO CHIEF COMMERCIAL OFFICER
* HLS THERAPEUTICS INC: QTRLY LOSS PER SHARE $0.15
* HLS THERAPEUTICS INC: OUTLOOK FY24 REVENUE $56.5-57.2
MILLION
Source text: ID:nCNW6qSwXa
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsBrief: Hls Therapeutics Increases Normal Course Issuer Bid
Brief: HLS Therapeutics Announces Q2 2026 Financial Results
Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand
Brief: HLS Therapeutics - Secures Nilemdo Reimbursement With Private Payers Covering 80% Of Privately Insured Canadians
Canada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group